HEART FAILURE: A COMPANION TO BRAUNWALD'S HEART DISEASE, 4TH EDITION

• Section 1 Basic Mechanisms of Heart Failure
1. Molecular Basis for Heart Failure
2. Cellular Basis for Heart Failure
3. Cellular Basis for Myocardial Regeneration and Repair
4. Myocardial Basis for Heart Failure: Role of Cardiac Interstitium
• Section 2 Mechanisms of Disease Progression in Heart Failure
5. Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure
6. Adrenergic Receptor Signaling in Heart Failure
7. Role of Innate Immunity in Heart Failure
8. Oxidative Stress in Heart Failure
9. Natriuretic Peptides in HF
10. Systolic Dysfunction in Heart Failure
11. Alterations in Ventricular Function: Diastolic Heart Failure
12. Alterations in Ventricular Structure: Role of Left Ventricular Remodeling and Reverse Remodeling in Heart Failure
13. Alterations in the Sympathetic and Parasympathetic Nervous Systems in Heart Failure
14. Alterations in the Peripheral Circulation in Heart Failure
15. Alterations in Kidney Function Associated with Heart Failure
16. Alterations in Skeletal Muscle in Heart Failure
17. Alterations in Cardiac Metabolism
• Section 3 Etiological Basis for Heart Failure
18. Epidemiology of Heart Failure
19. Heart Failure as a Consequence of Ischemic Heart Disease
20. Heart Failure as a Consequence of Dilated Cardiomyopathy
21. The Restrictive and Infiltrative Cardiomyopathies and Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
22. Cardiac Amyloidosis
23. Heart Failure as a Consequence of Hypertrophic Cardiomyopathy
24. Heart Failure as a Consequence of Genetic Cardiomyopathy
25. Heart Failure as a Consequence of Hypertension
26. Heart Failure as a Consequence of Valvular Heart Disease
27. Heart Failure as a Consequence of Congenital Heart Disease
28. Heart Failure as a Consequence of Viral and Nonviral Myocarditis
29. Heart Failure in the Developing World
30. Heart Failure and Human Immunodeficiency Virus
• Section 4 Clinical Assessment of Heart Failure
31. Clinical Evaluation of Heart Failure
32. Cardiac Imaging in Heart Failure
33. Biomarkers and Precision Medicine in Heart Failure
34. Hemodynamics in Heart Failure
• Section 5 Therapy for Heart Failure
35. Disease Prevention in Heart Failure
36. Management of Acute Decompensated Heart Failure Guidelines
37. Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction Guidelines: Management of Heart Failure with a Reduced Ejection Fraction
38. Management of Arrhythmias and Device Therapy in Heart Failure Guidelines
39. Treatment of Heart Failure with Preserved Ejection Fraction Guidelines
40. Management of Heart Failure in Special Populations: Older Patients, Women, and Racial/Ethnic Minority Groups
41. Gene and Stem-Cell Based Therapies in Heart Failure
42. Neuromodulation in Heart Failure
43. Pulmonary Hypertension
44. Cardiac Transplantation
45. Circulatory Assist Devices in Heart Failure
46. Cardio-Oncology and Heart Failure
47. Disease Management and Telemedicine in Heart Failure
48. Management of Comorbidities in Heart Failure
49. Quality and Outcomes in Heart Failure
50. Decision Making and Palliative Care in Advanced Heart Failure

Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald’s Heart Diseasehelps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients.

Authors
• G. Michael Felker, MD, MHS, FACC, FAHA, Professor of Medicine, Chief, Heart Failure Section, Division of Cardiology, Director, Clinical Research Unit, Duke Heart Center, Director of Heart Failure Research, Duke Clinical Research Institute, Durham, North Carolina.
• Douglas L. Mann, MD, Lewin Chair and Professor of Medicine, Cell Biology, and Physiology, Chief, Cardiovascular Division, Washington University School of Medicine; Cardiologist-in-Chief, Barnes-Jewish Hospital, St. Louis, Missouri